Siegel R.L. Miller K.D. Fuchs H.E. et al.

Cancer statistics, 2022.

CA Cancer J Clin. 72: 7-33Van Poppel H. Da Pozzo L. Albrecht W. et al.

A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma.

Eur Urol. 59: 543-552Janzen N.K. Kim H.L. Figlin R.A. et al.

Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease.

Urol Clin North Am. 30: 843-852Lam J.S. Leppert J.T. Belldegrun A.S. et al.

Novel approaches in the therapy of metastatic renal cell carcinoma.

World J Urol. 23: 202-212

The VHL Tumor Suppressor: Master Regulator of HIF.

Curr Pharm Des. 15: 3895-3903Stebbins C.E. Kaelin W.G. Pavletich N.P.

Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function.

Science. 284: 455-461Dutcher J.P. Flippot R. Fallah J. et al.

On the shoulders of giants: the evolution of renal cell carcinoma treatment—cytokines, targeted therapy, and immunotherapy.

Am Soc Clin Oncol Educ Book. : 418-435https://doi.org/10.1200/EDBK_280817Srivastava A. Doppalapudi S.K. Patel H.V. et al.

The roaring 2020s: a new decade of systemic therapy for renal cell carcinoma.

Curr Opin Oncol. 34: 234-242

Nivolumab: 5 years since FDA approval of the first checkpoint inhibitor for renal cell carcinoma.

Kidney Cancer. 5: 63-71Rini B.I. Plimack E.R. Stus V. et al.

Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.

N Engl J Med. 380: 1116-1127

Clinical review on the management of metastatic renal cell carcinoma.

JCO Oncol Pract. 18: 187-196Fishman M. Dutcher J.P. Clark J.I. et al.

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry.

J Immunother Cancer. 7: 84Iacovelli R. Alesini D. Palazzo A. et al.

Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials.

Cancer Treat Rev. 40: 271-275Choueiri T.K. Powles T. Burotto M. et al.

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

N Engl J Med. 384: 829-841Zambrana F. Carril-Ajuria L. Gómez de Liaño A. et al.

Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news.

Cancer Treat Rev. 99: 102239Powles T. Plimack E.R. Soulières D. et al.

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.

Lancet Oncol. 21: 1563-1573Kroeger N. Pantuck A.J. Wells J.C. et al.

Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.

Eur Urol. 68: 506-515Yu K.J. Keskin S.K. Meissner M.A. et al.

Renal cell carcinoma and pathologic nodal disease: Implications for American Joint Committee on Cancer staging.

Cancer. 124: 4023-4031Capitanio U. Jeldres C. Patard J.J. et al.

Stage-specific effect of nodal metastases on survival in patients with non-metastatic renal cell carcinoma.

BJU Int. 103: 33-37Rodríguez-Covarrubias F. Castillejos-Molina R. Sotomayor M. et al.

Impact of lymph node invasion and sarcomatoid differentiation on the survival of patients with locally advanced renal cell carcinoma.

Urol Int. 85: 23-29Vig S.V. Zan E. Kang S.K.

Imaging for Metastatic Renal Cell Carcinoma.

Urol Clin North Am. 47: 281-291Tadayoni A. Paschall A.K. Malayeri A.A.

Assessing lymph node status in patients with kidney cancer.

Transl Androl Urol. 7: 766-773Türkvatan A. Akdur P.O. Altinel M. et al.

Preoperative staging of renal cell carcinoma with multidetector CT.

Diagn Interv Radiol Ank Turk. 15: 22-30Kang D.E. White R.L. Zuger J.H. et al.

Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma.

J Urol. 171: 1806-1809Spahn M. Portillo F.J. Michel M.S. et al.

Color Duplex sonography vs. computed tomography: accuracy in the preoperative evaluation of renal cell carcinoma.

Eur Urol. 40: 337-342Studer U.E. Scherz S. Scheidegger J. et al.

Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases.

J Urol. 144: 243-245Johnson C.D. Dunnick N.R. Cohan R.H. et al.

Renal adenocarcinoma: CT staging of 100 tumors.

AJR Am J Roentgenol. 148: 59-63Nazim S.M. Ather M.H. Hafeez K. et al.

Accuracy of multidetector CT scans in staging of renal carcinoma.

Int J Surg Lond Engl. 9: 86-90Radadia K.D. Rivera-Núñez Z. Kim S. et al.

Accuracy of clinical nodal staging and factors associated with receipt of lymph node dissection at the time of surgery for nonmetastatic renal cell carcinoma.

Urol Oncol. 37: 577.e17-577.e25Capitanio U. Becker F. Blute M.L. et al.

Lymph node dissection in renal cell carcinoma.

Eur Urol. 60: 1212-1220Karmali R.J. Suami H. Wood C.G. et al.

Lymphatic drainage in renal cell carcinoma: back to the basics.

BJU Int. 114: 806-817

Studies on the main posterior lymph channels of the abdomen and their connections with the lymphatics of the genito-urinary system.

Am J Anat. 56: 409-443Brouwer O.R. Noe A. Olmos R.A.V. et al.

Lymphatic Drainage from Renal Cell Carcinoma along the Thoracic Duct Visualized with SPECT/CT.

Lymphat Res Biol. 11: 233-238Blom J.H.M. van Poppel H. Maréchal J.M. et al.

Radical Nephrectomy with and without Lymph-Node Dissection: Final Results of European Organization for Research and Treatment of Cancer (EORTC) Randomized Phase 3 Trial 30881.

Eur Urol. 55: 28-34Whitson J.M. Harris C.R. Reese A.C. et al.

Lymphadenectomy Improves Survival of Patients With Renal Cell Carcinoma and Nodal Metastases.

J Urol. 185: 1615-1620Crispen P.L. Breau R.H. Allmer C. et al.

Lymph Node Dissection at the Time of Radical Nephrectomy for High-Risk Clear Cell Renal Cell Carcinoma: Indications and Recommendations for Surgical Templates.

Eur Urol. 59: 18-23Capitanio U. Suardi N. Matloob R. et al.

Extent of lymph node dissection at nephrectomy affects cancer-specific survival and metastatic progression in specific sub-categories of patients with renal cell carcinoma (RCC).

BJU Int. 114: 210-215Farber N.J. Rivera-Núñez Z. Kim S. et al.

Trends and outcomes of lymphadenectomy for nonmetastatic renal cell carcinoma: A propensity score-weighted analysis of the National Cancer Database.

Urol Oncol Semin Orig Investig. 37: 26-32Gershman B. Thompson R.H. Moreira D.M. et al.

Radical Nephrectomy With or Without Lymph Node Dissection for Nonmetastatic Renal Cell Carcinoma: A Propensity Score-based Analysis.

Eur Urol. 71: 560-567Gershman B. Thompson R.H. Moreira D.M. et al.

Lymph Node Dissection is Not Associated with Improved Survival among Patients Undergoing Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Propensity Score Based Analysis.

J Urol. 197: 574-579Srivastava A. Rivera-Núñez Z. Kim S. et al.

Impact of pathologic lymph node-positive renal cell carcinoma on survival in patients without metastasis: Evidence in support of expanding the definition of stage IV kidney cancer.

Cancer. 126: 2991-3001Dehal A. Smith J.J. Nash G.M.

Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review—past, present and future.

J Gastrointest Oncol. 7https://doi.org/10.3978/j.issn.2078-6891.2015.112Makar A.P. Tropé C.G. Tummers P. et al.

Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer.

The Oncologist. 21: 745-754Margul D. Coleman R.L. Herzog T.J.

The current status of secondary cytoreduction in ovarian cancer: a systematic review.

Clin Adv Hematol Oncol HO. 18: 332-343Walther M.M. Patel B. Choyke P.L. et al.

Hypercalcemia in patients with metastatic renal cell carcinoma: effect of nephrectomy and metabolic evaluation.

J Urol. 158: 733-739Garfield D.H. Kennedy B.J.

Regression of metastatic renal cell carcinoma following nephrectomy.

Cancer. 30: 190-196Marcus S.G. Choyke P.L. Reiter R. et al.

Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy.

J Urol. 150: 463-466Gershman B. Moreira D.M. Boorjian S.A. et al.

Comprehensive Characterization of the Perioperative Morbidity of Cytoreductive Nephrectomy.

Eur Urol. 69: 84-91Roussel E. Campi R. Larcher A. et al.

Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma.

Eur Urol Oncol. 3: 523-529Flanigan R.C. Salmon S.E. Blumenstein B.A. et al.

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

N Engl J Med. 345: 1655-1659Mickisch G.H. Garin A. van Poppel H. et al.European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

Lancet Lond Engl. 358: 966-970Flanigan R.C. Mickisch G. Sylvester R. et al.

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.

J Urol. 171: 1071-1076Hanna N. Sun M. Meyer C.P. et al.

Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study.

J Clin Oncol Off J Am Soc Clin Oncol. 34: 3267-3275Conti S.L. Thomas I.C. Hagedorn J.C. et al.

Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era.

Int J Cancer. 134: 2245-2252Mathieu R. Pignot G. Ingles A. et al.

Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.

Urol Oncol. 33 ()Alhalabi O. Karam J.A. Tannir N.M.

Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology.

Curr Opin Urol. 29: 521-525Heng D.Y.C. Wells J.C. Rini B.I. et al.

Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Eur Urol. 66: 704-710Bhindi B. Abel E.J. Albiges L. et al.

Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.

Eur Urol. 75: 111-128Petrelli F. Coinu A. Vavassori I. et al.

Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Systematic Review With a Meta-Analysis.

Clin Genitourin Cancer. 14: 465-472Méjean A. Ravaud A. Thezenas S. et al.

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

N Engl J Med. 379: 417-427Bex A. Mulders P. Jewett M. et al.

Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.

JAMA Oncol. 5: 164-170Mejean A. Thezenas S. Chevreau C. et al.

Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on Carmena trial with focus on intermediate IMDC-risk population.

J Clin Oncol. 37: 4508Abu-Ghanem Y. van Thienen J.V. Blank C. et al.

Cytoreductive nephrectomy and exposure to sunitinib – a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial.

BJU Int. 130: 68-75Gross E.E. Li M. Yin M. et al.

A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy.

Urol Oncol Semin Orig Investig. https://doi.org/10.1016/j.urolonc.2022.08.013Bakouny Z. El Zarif T. Dudani S. et al.

Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium.

Eur Urol. https://doi.org/10.1016/j.eururo.2022.10.004

Multicenter Randomized Trial of Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma Receiving Checkpoint Inhibitors: A DaRenCa and NoRenCa Trial Evaluating the Impact of Surgery or No Surgery. The NORDIC-SUN-Trial. clinicaltrials.gov.

() ()

Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial). clinicaltrials.gov.

() ()

Cyto-KIK; TRIAL (CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy (Nivolumab) and Targeted Kinase Inhibition (Cabozantinib). clinicaltrials.gov.

() ()Alt A.L. Boorjian S.A. Lohse C.M. et al.

Survival after complete surgical resection of multiple metastases from renal cell carcinoma.

Cancer. 117: 2873-2882Dragomir A. Nazha S. Wood L.A. et al.

Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The Canadian Kidney Cancer information system experience.

Urol Oncol. 38: 799.e1-799.e10Wu K. Liu Z. Shao Y. et al.

Nomogram Predicting Survival to Assist Decision-Making of Metastasectomy in Patients With Metastatic Renal Cell Carcinoma.

Front Oncol. 10: 592243Piltz S. Meimarakis G. Wichmann M.W. et al.

Long-term results after pulmonary resection of renal cell carcinoma metastases.

Ann Thorac Surg. 73: 1082-1087Kim S.H. Park W.S. Park B. et al.

A Retrospective Analysis of the Impact of Metastasectomy on Prognostic Survival According to Metastatic Organs in Patients With Metastatic Renal Cell Carcinoma.

Front Oncol. 9: 413Sun M. Meyer C.P. Karam J.A. et al.

Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy.

Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 44: 1439-1445Kudelin N. Bölükbas S. Eberlein M. et al.

Metastasectomy with standardized lymph node dissection for metastatic renal cell carcinoma: an 11-year single-center experience.

Ann Thorac Surg. 96 (): 265-270Mikhail M. Chua K.J. Khizir L. et al.

Role of metastasectomy in the management of renal cell carcinoma.

Front Surg. 9: 943604Powles T. Tomczak P. Park S.H. et al.

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet Oncol. 23: 1133-1144Appleman L.J. Puligandla M. Pal S.K. et al.

Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: a trial of the ECOG-ACRIN cancer research group (E2810).

J Clin Oncol. 37: 4502